Literature DB >> 16189707

Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP.

Sara Lindström1, Fredrik Wiklund, Björn-Anders Jonsson, Hans-Olov Adami, Katarina Bälter, Anthony J Brookes, Jianfeng Xu, S Lilly Zheng, William B Isaacs, Jan Adolfsson, Henrik Grönberg.   

Abstract

The E-cadherin gene (CDH1) has been proposed as a prostate cancer (PC) susceptibility gene in several studies. Aberrant protein expression has been related to prognosis and progression in PC. In addition, a functional promoter SNP (rs16260) has been found to associate with PC risk. We performed a comprehensive genetic analysis of CDH1 by using the method of haplotype tagged SNPs in a large Swedish population-based case-control study consisting of 801 controls and 1,636 cases. In addition, Swedish PC families comprising a total of 157 cases sampled for DNA were analyzed for selected SNPs. Seven SNPs, including the promoter SNP rs16260, that captured over 96% of CDH1 haplotype variation were selected as haplotype tagging SNPs and analyzed for associated PC risk. We observed significant confirmation of rs16260 (P=0.003) for cases with a positive family history of PC (FH+) both in an independent case-control population and in PC families. In addition, a common haplotype (HapB, 25%) including the variant allele of rs16260 was associated (P=0.004) with PC risk among FH+ cases. The promoter SNP rs16260 as well as HapB were significantly transmitted to affected offspring in PC families. We report strong confirmation of the association between PC risk in FH+ cases and a functional CDH1 promoter SNP in an independent population. In conjunction with the biological importance of CDH1 our findings encourage further evaluation of genetic variation in CDH1 in relation to PC etiology. Due to the difficulties in replication of genetic association studies, this finding is unusual and novel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189707     DOI: 10.1007/s00439-005-0060-6

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  31 in total

Review 1.  Problems of reporting genetic associations with complex outcomes.

Authors:  Helen M Colhoun; Paul M McKeigue; George Davey Smith
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

2.  Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms.

Authors:  W M Howell; M Jobs; U Gyllensten; A J Brookes
Journal:  Nat Biotechnol       Date:  1999-01       Impact factor: 54.908

Review 3.  The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules.

Authors:  G B Grunwald
Journal:  Curr Opin Cell Biol       Date:  1993-10       Impact factor: 8.382

Review 4.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

5.  Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region.

Authors:  Akihiro Nakamura; Tomoe Shimazaki; Kazuhiro Kaneko; Minoru Shibata; Takuya Matsumura; Maho Nagai; Reiko Makino; Keiji Mitamura
Journal:  Mutat Res       Date:  2002-05-22       Impact factor: 2.433

6.  CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk.

Authors:  Haixin Lei; Sara Sjöberg-Margolin; Sima Salahshor; Barbro Werelius; Eva Jandáková; Kari Hemminki; Annika Lindblom; Igor Vorechovský
Journal:  Int J Cancer       Date:  2002-03-10       Impact factor: 7.396

7.  H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.

Authors:  Fredrik Lindmark; S Lilly Zheng; Fredrik Wiklund; Jeannette Bensen; Katarina Augustsson Bälter; Baoli Chang; Maria Hedelin; Jonathan Clark; Pär Stattin; Deborah A Meyers; Hans-Olov Adami; William Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  J Natl Cancer Inst       Date:  2004-08-18       Impact factor: 13.506

Review 8.  Mutations of the human E-cadherin (CDH1) gene.

Authors:  G Berx; K F Becker; H Höfler; F van Roy
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

9.  -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer.

Authors:  Björn-Anders Jonsson; Hans-Olov Adami; Maria Hägglund; Anders Bergh; Ingela Göransson; Pär Stattin; Fredrik Wiklund; Henrik Grönberg
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

Review 10.  The complex genetic epidemiology of prostate cancer.

Authors:  Daniel J Schaid
Journal:  Hum Mol Genet       Date:  2004-01-28       Impact factor: 6.150

View more
  10 in total

1.  Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.

Authors:  Zheng Chang; Hongbing Zhou; Yi Liu
Journal:  Tumour Biol       Date:  2014-07-24

2.  The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis.

Authors:  Li-Xin Qiu; Ru-Tian Li; Jian-Bing Zhang; Wen-Zhao Zhong; Jian-Ling Bai; Bao-Rui Liu; Ming-Hua Zheng; Xiao-Ping Qian
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

3.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

4.  Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma.

Authors:  Beatrice Susanne Malmer; Maria Feychting; Stefan Lönn; Sara Lindström; Henrik Grönberg; Anders Ahlbom; Judy Schwartzbaum; Anssi Auvinen; Helle Collatz-Christensen; Christoffer Johansen; Anne Kiuru; Nadejda Mudie; Tiina Salminen; Minouk J Schoemaker; Anthony J Swerdlow; Roger Henriksson
Journal:  J Neurooncol       Date:  2006-12-07       Impact factor: 4.506

5.  Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.

Authors:  Lin Wang; Guiying Wang; Chenqi Lu; Bo Feng; Jiuhong Kang
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

6.  The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis.

Authors:  Kan He; Wenwen Lv; Dongni Zheng; Fei Cheng; Tao Zhou; Shoudong Ye; Qian Ban; Qilong Ying; Bei Huang; Lei Chen; Guohua Wu; Dahai Liu
Journal:  Oncotarget       Date:  2015-04-20

Review 7.  Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example.

Authors:  Gongcheng Li; Tiejun Pan; Dan Guo; Long-Cheng Li
Journal:  Mol Biol Int       Date:  2014-09-02

8.  A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.

Authors:  Giuseppina Pisignano; Sara Napoli; Marco Magistri; Sarah N Mapelli; Chiara Pastori; Stefano Di Marco; Gianluca Civenni; Domenico Albino; Claudia Enriquez; Sara Allegrini; Abhishek Mitra; Gioacchino D'Ambrosio; Maurizia Mello-Grand; Giovanna Chiorino; Ramon Garcia-Escudero; Gabriele Varani; Giuseppina M Carbone; Carlo V Catapano
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

9.  A short guide to hereditary diffuse gastric cancer.

Authors:  Parry Guilford; Vanessa Blair; Helen More; Bostjan Humar
Journal:  Hered Cancer Clin Pract       Date:  2007-12-15       Impact factor: 2.857

10.  A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population.

Authors:  Soroush Nasri; Helen More; Francesco Graziano; Annamaria Ruzzo; Emily Wilson; Anita Dunbier; Cushla McKinney; Tony Merriman; Parry Guilford; Mauro Magnani; Bostjan Humar
Journal:  BMC Cancer       Date:  2008-05-15       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.